Influence of formulation and route of administration on ketamine's safety and tolerability: systematic review

被引:15
作者
Glue, Paul [1 ]
Russell, Bruce [2 ]
Medlicott, Natalie J. [2 ]
机构
[1] Univ Otago, Sch Med Sci, Psychol Med, POB 913, Dunedin, New Zealand
[2] Univ Otago, Sch Pharm, Dunedin, New Zealand
关键词
Ketamine formulation; First pass metabolism; Pharmacokinetics; Safety; Dissociation; NORKETAMINE PLASMA-CONCENTRATIONS; S-KETAMINE; RECTAL KETAMINE; ORAL KETAMINE; PHARMACOKINETICS; BIOAVAILABILITY; ESKETAMINE; NASAL; PAIN; IV;
D O I
10.1007/s00228-020-03047-z
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose Ketamine has rapid-onset antidepressant effects in patients with treatment-resistant depression. Common side effects include dissociation (a sense of detachment from reality) and increases in systolic and diastolic blood pressure. The objective of this structured review was to examine the effect of ketamine formulation and route of administration on its pharmacokinetics, safety and tolerability, to identify formulation characteristics and routes of administration that might minimise side effects. Methods This was a structured review of published ketamine pharmacokinetics, safety and tolerability data for any ketamine formulation. The ratio of ketamine:norketamine was calculated from reported C-max values, as a measure of first pass metabolism. The effect of formulation and route of administration on safety was evaluated by measuring mean changes in systolic blood pressure and tolerability by changes in dissociation ratings. Data were correlated using Spearman's method. Results A total of 41 treatment arms were identified from 21 publications, and included formulation development studies in healthy volunteers, and studies in clinical populations (patients undergoing anaesthesia, or being treated for pain or depression). Ketamine:norketamine ratios were strongly positively correlated with change in dissociation ratings (r = 0.89) and change in blood pressure (r = 0.96), and strongly negatively correlated with ketamine T-max (r = - 0.87; p < 0.00001 for all). Ketamine T-max strongly positively correlated with a change in dissociation ratings (r = - 0.96) and change in blood pressure (r = - 0.99; p < 0.00001 for all). Conclusion Ketamine formulations that maximize first pass metabolism and delay T-max will be better tolerated and safer than formulations which lack those characteristics.
引用
收藏
页码:671 / 676
页数:6
相关论文
共 36 条
[1]  
Bitter C, 2010, THESIS
[2]   Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS) [J].
Bremner, JD ;
Krystal, JH ;
Putnam, FW ;
Southwick, SM ;
Marmar, C ;
Charney, DS ;
Mazure, CM .
JOURNAL OF TRAUMATIC STRESS, 1998, 11 (01) :125-136
[3]   Exploring the pharmacokinetics of oral ketamine in children undergoing burns procedures [J].
Brunette, Katharine E. J. ;
Anderson, Brian J. ;
Thomas, Jennifer ;
Wiesner, Lubbe ;
Herd, David W. ;
Schulein, Simone .
PEDIATRIC ANESTHESIA, 2011, 21 (06) :653-662
[4]   Development of a Sublingual/Oral Formulation of Ketamine for Use in Neuropathic Pain Preliminary Findings from a Three-Way Randomized, Crossover Study [J].
Chong, Chui ;
Schug, Stephan A. ;
Page-Sharp, Madhu ;
Jenkins, Barry ;
Ilett, Kenneth F. .
CLINICAL DRUG INVESTIGATION, 2009, 29 (05) :317-324
[5]   BIOAVAILABILITY, PHARMACOKINETICS, AND ANALGESIC ACTIVITY OF KETAMINE IN HUMANS [J].
CLEMENTS, JA ;
NIMMO, WS ;
GRANT, IS .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1982, 71 (05) :539-542
[6]   Hydrogel-forming microneedle arrays as a therapeutic option for transdermal esketamine delivery [J].
Courtenay, Aaron J. ;
McAlister, Emma ;
McCrudden, Maeliosa T. C. ;
Vora, Lalit ;
Steiner, Lilach ;
Levin, Galit ;
Levy-Nissenbaum, Etgar ;
Shterman, Nava ;
Kearney, Mary-Carmel ;
McCarthy, Helen O. ;
Donnelly, Ryan F. .
JOURNAL OF CONTROLLED RELEASE, 2020, 322 :177-186
[7]   Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study [J].
Domany, Yoav ;
Bleich-Cohen, Maya ;
Tarrasch, Ricardo ;
Meidan, Roi ;
Litvak-Lazar, Olga ;
Stoppleman, Nadav ;
Schreiber, Shaul ;
Bloch, Miki ;
Hendler, Talma ;
Sharon, Haggai .
BRITISH JOURNAL OF PSYCHIATRY, 2019, 214 (01) :20-26
[8]   Ketamine for analgosedation in critically ill patients [J].
Erstad, Brian L. ;
Patanwala, Asad E. .
JOURNAL OF CRITICAL CARE, 2016, 35 :145-149
[9]   Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing [J].
Fanta, Samuel ;
Kinnunen, Mari ;
Backman, Janne T. ;
Kalso, Eija .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 71 (04) :441-447
[10]   Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: open label pilot study [J].
Glue, Paul ;
Medlicott, Natalie J. ;
Neehoff, Shona ;
Surman, Peter ;
Lam, Fred ;
Hung, Noelyn ;
Hung, Cheung-tak .
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2020, 10